Literature DB >> 23765772

Predicting the presence of hepatitis B virus surface antigen in Chinese patients by pathology data mining.

Guifang Shang1, Alice Richardson, Michelle E Gahan, Simon Easteal, Stephen Ohms, Brett A Lidbury.   

Abstract

Hepatitis B virus (HBV) is a pathogen of worldwide health significance, associated with liver disease. A vaccine is available, yet HBV prevalence remains a concern, particularly in developing countries. Pathology laboratories have a primary role in the diagnosis and monitoring of HBV infection, through hepatitis B surface antigen (HBsAg) immunoassay and associated tests. Analysis of HBsAg immunoassay and associated pathology data from 821 Chinese patients applied 10-fold cross-validation to establish classification decision trees (CDTs), with CDT results used subsequently to develop a logistic regression model. The robustness of logistic regression model was confirmed by the Hosmer-Lemeshow test, Pseudo-R(2) and an area under receiver operating characteristic curve (AUROC) result that showed the logistic regression model was capable of accurately discriminating the HBsAg positive from HBsAg negative patients at 95% accuracy. Overall CDT sensitivity and specificity was 94.7% (± 5.0%) and 89.5% (± 5.7%), respectively, close to the sensitivity and specificity of the immunoassay, providing an alternative to predict HBsAg status. Both the CDT and logistic regression modeling demonstrated the importance of the routine pathology variables alanine aminotransferase (ALT), serum albumin (ALB), and alkaline phosphatase (ALP) to accurately predict HBsAg status in a Chinese patient cohort. The study demonstrates that CDTs and a linked logistic regression model applied to routine pathology data were an effective supplement to HBsAg immunoassay, and a possible replacement method where immunoassays are not requested or not easily available for the laboratory diagnosis of HBV infection.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23765772     DOI: 10.1002/jmv.23609

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

1.  Gamma-Glutamyl Transferase (GGT) Is the Leading External Quality Assurance Predictor of ISO15189 Compliance for Pathology Laboratories.

Authors:  Brett A Lidbury; Gus Koerbin; Alice M Richardson; Tony Badrick
Journal:  Diagnostics (Basel)       Date:  2021-04-13

2.  Mining disease risk patterns from nationwide clinical databases for the assessment of early rheumatoid arthritis risk.

Authors:  Chu Yu Chin; Meng Yu Weng; Tzu Chieh Lin; Shyr Yuan Cheng; Yea Huei Kao Yang; Vincent S Tseng
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

Review 3.  Advanced molecular surveillance of hepatitis C virus.

Authors:  Livia Maria Gonçalves Rossi; Alejandro Escobar-Gutierrez; Paula Rahal
Journal:  Viruses       Date:  2015-03-13       Impact factor: 5.048

4.  Enhancement of hepatitis virus immunoassay outcome predictions in imbalanced routine pathology data by data balancing and feature selection before the application of support vector machines.

Authors:  Alice M Richardson; Brett A Lidbury
Journal:  BMC Med Inform Decis Mak       Date:  2017-08-14       Impact factor: 2.796

5.  Predicting Hepatitis B Virus Infection Based on Health Examination Data of Community Population.

Authors:  Ying Wang; Zhicheng Du; Wayne R Lawrence; Yun Huang; Yu Deng; Yuantao Hao
Journal:  Int J Environ Res Public Health       Date:  2019-12-02       Impact factor: 3.390

6.  Predicting liver disease post hepatitis virus infection: In silico pathology and pattern recognition.

Authors:  Brett A Lidbury
Journal:  EBioMedicine       Date:  2018-08-23       Impact factor: 8.143

7.  Clinical prediction of HBV and HCV related hepatic fibrosis using machine learning.

Authors:  Runmin Wei; Jingye Wang; Xiaoning Wang; Guoxiang Xie; Yixing Wang; Hua Zhang; Cheng-Yuan Peng; Cynthia Rajani; Sandi Kwee; Ping Liu; Wei Jia
Journal:  EBioMedicine       Date:  2018-08-10       Impact factor: 8.143

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.